(Q73280034)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9123735%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9123735%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9123735%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

A Harrison

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9123735%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

English

0 references

publication date

1 March 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9123735%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9123735%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9123735%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

3A Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9123735%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

38-45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9123735%20AND%20SRC:MED&resulttype=core&format=json

The effect of dose on local control of prostate cancer.

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Tumor control in definitive irradiation of localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ml

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Salvage Radical Prostatectomy for Radiorecurrent Adenocarcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

Radical prostatectomy after definitive radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900168-4

7 January 2021

10.1016/S0090-4295(97)00168-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9123735%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference